AgomAb Therapeutics NV (AGMB)

AgomAb Therapeutics NV Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	86.42	171.46
Short-Term Investments	30.1	-
Cash & Short-Term Investments	116.51	171.46
Cash Growth	-32.05%	-
Other Current Assets	4.72	2.39
Total Current Assets	121.24	173.85
Net Property, Plant & Equipment	1.59	1.99
Other Intangible Assets	20.11	20.11
Goodwill	8.61	8.61
Long-Term Investments	0.01	0.01
Other Long-Term Assets	2.15	1.79
Total Assets	153.71	206.36
Accounts Payable	10.27	8.05
Accrued Expenses	1.55	0.8
Current Portion of Leases	0.25	0.27
Other Current Liabilities	6.53	-
Total Current Liabilities	18.59	9.13
Long-Term Leases	1.01	1.27
Other Long-Term Liabilities	3.21	7.88
Total Long-Term Liabilities	4.22	9.15
Total Liabilities	22.8	18.28
Common Stock	223.07	223.07
Additional Paid-in Capital	90.51	85.16
Accumulated Other Comprehensive Income	-0.97	-0.97
Retained Earnings	-181.71	-119.18
Shareholders' Equity	130.9	188.08
Total Liabilities & Equity	153.71	206.36
Total Debt	1.25	1.55
Net Cash (Debt)	115.26	169.91
Net Cash Growth	-32.17%	-
Net Cash Per Share	213.00	314.00
Book Value	130.9	188.08
Book Value Per Share	241.91	347.57
Tangible Book Value	102.18	159.36
Tangible Book Value Per Share	188.83	294.50

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q